<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">biob</journal-id><journal-title-group><journal-title xml:lang="ru">Биобезопасность и Биотехнология</journal-title><trans-title-group xml:lang="en"><trans-title>Biosafety and Biotechnology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2707-7241</issn><issn pub-type="epub">2957-5702</issn><publisher><publisher-name>Научно-исследовательский институт проблем биологической безопасности</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">biob-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МИКРОБИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MICROBIOLOGY</subject></subj-group></article-categories><title-group><article-title>СИНТЕЗ ПРАЙМЕРОВ И НАРАБОТКА ЗНАЧИМЫХ ГЕНОВ B.1.1.7 (АЛЬФА) ВАРИАНТА ВИРУСА SARS-CoV-2</article-title><trans-title-group xml:lang="en"><trans-title>SYNTHESIS OF PRIMERS AND DEVELOPMENT OF SIGNIFICANT GENES OF B.1.1.7 (ALPHA) VARIANT OF THE SARS-CoV-2 VIRUS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Усербаев</surname><given-names>Б. С.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурашев</surname><given-names>Е. Д.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мелисбек</surname><given-names>А. М.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширинбеков</surname><given-names>М. Ж.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">РГП «Научно-исследовательский институт проблем биологической безопасности»<country>Казахстан</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2022</year></pub-date><volume>0</volume><issue>8</issue><fpage>41</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Усербаев Б.С., Бурашев Е.Д., Мелисбек А.М., Ширинбеков М.Ж., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Усербаев Б.С., Бурашев Е.Д., Мелисбек А.М., Ширинбеков М.Ж.</copyright-holder><copyright-holder xml:lang="en">Усербаев Б.С., Бурашев Е.Д., Мелисбек А.М., Ширинбеков М.Ж.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.biosafety.kz/jour/article/view/9">https://journal.biosafety.kz/jour/article/view/9</self-uri><abstract><p>Угроза заражения человека коронавирусом стала известна еще в 60-х годах прошлого века. С тех пор зоонозная коронавирусная инфекция распространилась среди людей и в начале 21-го века было две крупные эпидемии. Показатель заражения людей коронавирусной инфекцией быстро распространился и вызвал серьезную обеспокоенность в мире. Коронавирусная инфекция со временем претерпела различные генетические изменения, в результате в 2019 году в городе Ухань, КНР коронавирусная инфекция распространилась среди людей. Из-за широкого распространения коронавирусной инфекции в мире ВОЗ объявила пандемию 11 марта 2020 года. Коронавирусная инфекция SARS-CoV-2 зарегистрирована около в 200 странах мира и со временем претерпела различные генетические изменения. Из-за генетических изменений в Великобритании осенью 2020 года появился новый штамм коронавирусной инфекции. Для определения генетических изменений коронавирусной инфекции и для их различения, в нашей лаборатории было разработано 65 пар праймеров для получения полного геномного сиквенса. Разработаны специальные праймеры для наработки значимых генов вируса SARS-CoV-2. Разработанные праймеры позволяют получить полную информацию о генах вирусов SARS-CoV-2.</p><p>Представленные праймеры можно использовать в целях идентификации и наработки полного генома вируса SARS-CoV-2.</p></abstract><trans-abstract xml:lang="en"><p>The threat of human infection with coronavirus became known back in the 60s of the last century. Since then, zoonotic coronavirus infection has spread among people and there were two major epidemics at the beginning of the 21st century. The rate of human infection with coronavirus infection spread rapidly and caused serious concern in the world. Coronavirus infection has undergone various genetic changes over time, as a result, in 2019, in Wuhan, China, coronavirus infection spread among people. Due to the widespread spread of coronavirus infection in the world, WHO declared a pandemic on March 11, 2020. Coronavirus infection SARS-CoV-2 has been registered in about 200 countries around the world and has undergone various genetic changes over time. Due to genetic changes, a new strain of coronavirus infection appeared in the UK in the autumn of 2020. To determine the genetic changes of coronavirus infection and to study them, 65 pairs of primers were developed in the Collective Use Laboratory to obtain the complete nucleotide sequence of the SARS-CoV-2 virus. Specific primers have been developed for the development of significant genes of the SARS-CoV-2 virus. The developed primers allow us to obtain complete information about the genes of SARS-CoV-2 viruses. The presented primers can be used for identification and development of the complete genome of the SARS-CoV-2 virus</p></trans-abstract><kwd-group xml:lang="ru"><kwd>SARS-CoV-2</kwd><kwd>мутация</kwd><kwd>ПЦР</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>mutation</kwd><kwd>PCR</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kahn J.S., McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24, Suppl: S223–S227, 2005. doi:10.1097/01.inf.0000188166.17324.60.</mixed-citation><mixed-citation xml:lang="en">Kahn J.S., McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24, Suppl: S223–S227, 2005. doi:10.1097/01.inf.0000188166.17324.60.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev, 2005. – Р. 635-664. doi:10.1128/MMBR.69.4.635-664.2005</mixed-citation><mixed-citation xml:lang="en">Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev, 2005. – Р. 635-664. doi:10.1128/MMBR.69.4.635-664.2005</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lu G., Wang Q., Gao1 G.F. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. – 2015. – Р. 468–478.</mixed-citation><mixed-citation xml:lang="en">Lu G., Wang Q., Gao1 G.F. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. – 2015. – Р. 468–478.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sarah L., Andrew L., Aviv O. COVID-19: A review of the proposed pharmacological treatments. European Journal of Pharmacology, 2020. – Vol.886. – Р. 173-251.</mixed-citation><mixed-citation xml:lang="en">Sarah L., Andrew L., Aviv O. COVID-19: A review of the proposed pharmacological treatments. European Journal of Pharmacology, 2020. – Vol.886. – Р. 173-251.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [Internet]. Geneva (Switzerland): World Health Organization; 2020 [cited 2020 Mar 11]. Available from: https://www.who.int/</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [Internet]. Geneva (Switzerland): World Health Organization; 2020 [cited 2020 Mar 11]. Available from: https://www.who.int/</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/table</mixed-citation><mixed-citation xml:lang="en">WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/table</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tracking SARS-CoV-2 variants https://www.who.int/en/activities/tracking-SARS-CoV-2 variants/</mixed-citation><mixed-citation xml:lang="en">Tracking SARS-CoV-2 variants https://www.who.int/en/activities/tracking-SARS-CoV-2 variants/</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Explained: Why WHO named Covid-19 variants first found in India as ‘Kappa’ and ‘Delta’ | India News ‑ Times of India (англ.). The Times of India. Дата обращения: 20 января 2022.</mixed-citation><mixed-citation xml:lang="en">Explained: Why WHO named Covid-19 variants first found in India as ‘Kappa’ and ‘Delta’ | India News ‑ Times of India (англ.). The Times of India. Дата обращения: 20 января 2022.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern (англ.). www.who.int. Дата обращения: 20 января 2022</mixed-citation><mixed-citation xml:lang="en">WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern (англ.). www.who.int. Дата обращения: 20 января 2022</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rambaut A., Loman N., Pybus O., Barclay W., Barrett J., Carabelli A., Connor T., Peacock T., Robertson D.L., Volz E. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations.</mixed-citation><mixed-citation xml:lang="en">Rambaut A., Loman N., Pybus O., Barclay W., Barrett J., Carabelli A., Connor T., Peacock T., Robertson D.L., Volz E. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Inside the B.1.1.7 Coronavirus Variant. https://www.nytimes.com/interactive/2021/health/coronavirus-mutations-B117-variant.html</mixed-citation><mixed-citation xml:lang="en">Inside the B.1.1.7 Coronavirus Variant. https://www.nytimes.com/interactive/2021/health/coronavirus-mutations-B117-variant.html</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Li D., Zhang J., Li J. Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2. Theranostics, 2020. – Р. 7150-62. https://doi.org/10.7150/thno.47649</mixed-citation><mixed-citation xml:lang="en">Li D., Zhang J., Li J. Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2. Theranostics, 2020. – Р. 7150-62. https://doi.org/10.7150/thno.47649</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
